SelegilineBenefits, Dosage & Interactions

Selegiline exerts its primary therapeutic effects by selectively inhibiting monoamine oxidase B (MAO-B). MAO-B is an enzyme predominantly found in the brain, responsible for the breakdown of dopamine. By inhibiting MAO-B, selegiline reduces the metabolic degradation of dopamine in the synapse, thereby increasing the availability and prolonging the action of dopamine in the central nervous system (DrugBank, PubChem). At therapeutic doses used for Parkinson's disease, selegiline's inhibition of MAO-B is considered highly selective. However, at higher doses, its selectivity can diminish, and it may begin to inhibit monoamine oxidase A (MAO-A) as well. MAO-A is involved in the metabolism of other neurotransmitters like serotonin and norepinephrine. This loss of selectivity at higher doses is clinically significant because MAO-A inhibition can lead to serious interactions with certain foods (tyramine-containing foods) and medications. Selegiline is metabolized in the liver into several active metabolites, including L-amphetamine and L-methamphetamine. While these metabolites are pharmacologically active, their contribution to the overall therapeutic effects and side effect profile of selegiline is generally considered minor at standard clinical doses compared to the MAO-B inhibition itself (FDA label). The exact mechanism by which selegiline exerts antidepressant effects when administered via transdermal patch for depression is thought to involve both MAO-A and MAO-B inhibition within the brain, while minimizing systemic MAO-A inhibition that could lead to dietary restrictions (Mayo Clinic).

Selegiline is primarily recognized for its benefits in the management of Parkinson's disease and, in certain formulations, for major depressive disorder. * **Parkinson's Disease Monotherapy:** In early Parkinson's disease, selegiline may be used as a monotherapy to delay the need for levodopa treatment. It helps to alleviate some motor symptoms by increasing dopamine levels in the brain (Mayo Clinic). * **Adjunctive Therapy in Parkinson's Disease:** When used in conjunction with levodopa-carbidopa therapy, selegiline can help reduce 'wearing-off' phenomena and 'off' times, where the effects of levodopa diminish before the next dose. By extending the availability of dopamine, it can improve motor fluctuations and overall motor function (NIH NLM Bookshelf). * **Delaying Disease Progression (controversial):** Early studies suggested a neuroprotective effect, potentially slowing the progression of Parkinson's disease. However, more extensive clinical trials have largely failed to definitively confirm this neuroprotective benefit, and it remains a topic of ongoing research and discussion among clinicians (Cochrane Review). * **Major Depressive Disorder:** A transdermal patch formulation of selegiline is approved for the treatment of major depressive disorder. This route of administration is designed to deliver selegiline directly into the systemic circulation, allowing for brain MAO-A and MAO-B inhibition linked to antidepressant effects, while potentially reducing the risk of dietary restrictions associated with oral non-selective MAO inhibitors (FDA label).

Evidence supporting the use of selegiline in Parkinson's disease and major depressive disorder comes from various clinical trials and reviews. For Parkinson's disease, a Cochrane Review examining selegiline monotherapy in early Parkinson's disease found that it led to a small but statistically significant delay in the time to require levodopa therapy. However, the review noted that improvements in overall motor function were modest. When used as an adjunct to levodopa, clinical studies have demonstrated selegiline's ability to improve motor fluctuations. For instance, studies cited by the FDA label for oral selegiline show reductions in 'off' time and improvements in daily activities for patients experiencing motor fluctuations on levodopa therapy. The neuroprotective hypothesis of selegiline, suggesting it could slow Parkinson's disease progression, arose from a study known as the DATATOP study. While this study initially showed a delay in the need for levodopa in the selegiline-treated group, subsequent re-evaluation and larger trials, such as the Parkinson's Study Group PRECEPT study, did not definitively confirm a neuroprotective effect. The observed benefit was largely attributed to symptomatic relief (Examine.com). For major depressive disorder, the transdermal selegiline patch has been shown to be effective in placebo-controlled trials. The FDA approval for this indication is based on findings from trials demonstrating its efficacy in improving depression symptoms (FDA label). These trials indicate that the transdermal route alters the pharmacokinetic profile sufficiently to allow for a broader MAO inhibition without requiring the strict dietary restrictions typically associated with oral non-selective MAO inhibitors.

Selegiline can cause various side effects, which may differ depending on the dose, formulation (oral vs. transdermal patch), and whether it is used alone or with other medications. Common side effects often include: * **Gastrointestinal:** Nausea, dry mouth, stomach pain, constipation. * **Neurological/Psychiatric:** Dizziness, insomnia, headache, confusion, hallucinations (especially in Parkinson's patients when used with levodopa), dyskinesia (involuntary movements, particularly with levodopa use), anxiety, vivid dreams. * **Cardiovascular:** Orthostatic hypotension (a drop in blood pressure upon standing), palpitations. * **Other:** Rash or skin irritation (with transdermal patch), back pain. Serotonin syndrome is a rare but serious side effect that can occur when selegiline is combined with other serotonergic drugs (see `do_not_mix_md` section). Symptoms include agitation, hallucinations, rapid heartbeat, fever, sweating, muscle rigidity, and severe nausea or diarrhea (MedlinePlus). Though generally well-tolerated at prescribed doses, any new or worsening side effects should be reported to a healthcare professional. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Several warnings and precautions are associated with the use of selegiline. * **Hypertensive Crisis Risk:** Although oral selegiline is generally selective for MAO-B at recommended doses, this selectivity can be lost at higher doses, leading to inhibition of MAO-A. This increases the risk of a hypertensive crisis if tyramine-containing foods are consumed. While the transdermal patch may not require strict dietary restrictions at recommended doses, patients should still be advised about the potential for interaction with very large amounts of tyramine (FDA label). * **Serotonin Syndrome:** There is a significant risk of developing serotonin syndrome when selegiline is used concurrently with other serotonergic agents, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, and triptans. This condition can be life-threatening and requires immediate medical attention (Mayo Clinic). * **Exacerbation of Psychosis:** Selegiline, particularly in combination with dopaminergic agents like levodopa, can exacerbate psychotic symptoms, including hallucinations and delusions, in patients with Parkinson's disease or other predispositions. * **Falls and Dizziness:** Orthostatic hypotension and dizziness are common side effects, especially in elderly patients or those also taking antihypertensive medications, increasing the risk of falls. * **Melanoma:** Some studies have suggested a potential association between Parkinson's disease and an increased risk of melanoma. It is unclear whether selegiline itself contributes to this risk, but regular skin examinations are recommended (NIH NLM Bookshelf). This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Selegiline is contraindicated in certain situations due to potential risks. * **Hypersensitivity:** Individuals with a known hypersensitivity to selegiline or any component of its formulation should not use it. * **Concurrent Use of Certain Medications:** Due to the risk of serotonin syndrome or hypertensive crisis, selegiline is absolutely contraindicated with: * Other MAO inhibitors (e.g., phenelzine, tranylcypromine, isocarboxazid, linezolid, methylene blue) – a wash-out period is usually required between discontinuing one MAOI and starting another. * Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). * Tricyclic antidepressants (TCAs). * Meperidine and other opioids like tramadol, methadone, propoxyphene, and dextromethorphan. * St. John's Wort. * Buspirone. * **Pheochromocytoma:** Patients with pheochromocytoma, a tumor of the adrenal gland that secretes high levels of catecholamines, should not use selegiline due to the risk of inducing a hypertensive crisis. * **Severe Renal or Hepatic Impairment:** Caution is advised, and dose adjustments may be necessary in patients with significant liver or kidney dysfunction, as these organs are crucial for selegiline's metabolism and excretion (FDA label). This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Combining selegiline with certain substances can lead to severe and potentially life-threatening adverse reactions. It is critical to inform your healthcare provider about all medications, supplements, and dietary habits before starting selegiline. * **Other Monoamine Oxidase Inhibitors (MAOIs):** Combining selegiline with other MAOIs (e.g., phenelzine, tranylcypromine, isocarboxazid, linezolid, methylene blue) is strictly contraindicated. This combination can lead to a hypertensive crisis, characterized by dangerously high blood pressure, severe headache, rapid heart rate, and other serious symptoms (MedlinePlus). * **Serotonergic Drugs:** A wide range of drugs that increase serotonin levels should not be used with selegiline due to the high risk of serotonin syndrome. These include: * **SSRIs** (e.g., fluoxetine, sertraline, paroxetine, citalopram). * **SNRIs** (e.g., venlafaxine, duloxetine). * **Tricyclic Antidepressants** (e.g., amitriptyline, imipramine). * **Triptans** (used for migraines, e.g., sumatriptan, zolmitriptan). * **Certain Opioid Analgesics:** Meperidine, tramadol, methadone, propoxyphene, and dextromethorphan. * **St. John's Wort.** * **Buspirone.** * **Stimulants** (e.g., amphetamines, methylphenidate) and **Tetracyclic Antidepressants** (e.g. mirtazapine) can also increase serotonin and noradrenaline levels, requiring caution. * **Tyramine-rich Foods (at higher doses or with non-selective forms):** Although oral selegiline is selective for MAO-B at typical Parkinson's doses, and the transdermal patch formulation aims to bypass this interaction, higher doses or individual sensitivities can lead to MAO-A inhibition. This can result in a hypertensive crisis upon consumption of foods rich in tyramine, such as aged cheeses, cured meats, fava beans, tap beers, and soy products. Always follow specific dietary guidance from your clinician based on your selegiline prescription (Mayo Clinic). * **Dopaminergic Agonists (e.g., bromocriptine, pramipexole):** While often used adjunctively in Parkinson's, combining selegiline with high doses of other dopaminergic agents can increase the risk of side effects like dyskinesia, hallucinations, and orthostatic hypotension. * **Sympathomimetic Agents:** Medications that stimulate the sympathetic nervous system (e.g., decongestants like pseudoephedrine, phenylephrine, or appetite suppressants) can cause a severe increase in blood pressure when combined with selegiline. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

The typical timing for oral selegiline administration is in the morning. This recommendation is often made to minimize the potential for insomnia, which can be a side effect given its activating properties and known active metabolites (L-amphetamine and L-methamphetamine) (FDA label). For this reason, doses are usually taken with breakfast and/or lunch. For the transdermal patch formulation, it is typically applied once daily, and the specific time of day for application may be less critical regarding insomnia, though consistency in application time is generally advised for maintaining steady drug levels. Patients should always follow their prescribing clinician's specific instructions regarding the timing and application of selegiline, as individual needs and the formulation used may dictate variations in schedule. Selegiline can generally be taken either with or without food, but specific instructions from your clinician should always be followed.